PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 498/04, A61K 31/535 // (C07D 498/04, 261:00, 223:00) — A1

(11) International Publication Number: WO 96/14320

(43) International Publication Date: 17 May 1996 (17.05.96)

(21) International Application Number: PCT/EP95/04196

(22) International Filing Date: 25 October 1995 (25.10.95)

(30) Priority Data:
94203178.2 2 November 1994 (02.11.94) EP
(34) Countries for which the regional or international application was filed: DE et al.
457,968 31 May 1995 (31.05.95) US

(60) Parent Application or Grant
(63) Related by Continuation
US 457,968 (CON)
Filed on 31 May 1995 (31.05.95)

(71) Applicant (*for all designated States except US*): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): SIPIDO, Victor, Karel [BE/BE]; Winterkoningstraat 37, B-2170 Merksem (BE). FERNANDEZ-GADEA, Francisco Javier [ES/ES]; Sagra, 20, Cerro De Las Perdices (Barga), E-45593 Toledo (ES). ANDRES-GIL, José Ignacio [ES/ES]; Vesubiana, 22, Getafe-Sector 3, E-28905 Madrid (ES). MEERT, Theo, Frans [BE/BE]; Pierstraat 42, B-2840 Rumst (BE). GIL-LOPETEGUI, Pilar [ES/ES]; Santa Ursula, 10, E-45002 Toledo (ES).

(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).


EG 9701836-0

Published
With international search report.

RMTP copy

(54) Title: SUBSTITUTED TETRACYCLIC AZEPINE DERIVATIVES WHICH HAVE AFFINITY FOR 5-HT2 RECEPTORS

(57) Abstract



(I)

This invention concerns the compounds of formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the *N*-oxide forms thereof. In formula (I) R^1 and R^2 each independently are hydrogen; C_{1-6}alkyl; C_{1-6}alkylcarbonyl; trihalomethylcarbonyl; C_{1-6}alkyl substituted with hydroxy, C_{1-6}alkyloxy, carboxyl, C_{1-6}alkylcarbonyloxy, C_{1-6}alkyloxycarbonyl or aryl; or R^1 and R^2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substitued heterocycle; R^3, R^4, R^5, R^6, R^9, R^{10}, R^{11} or R^{12} each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C_{1-6}alkyl)-amino, C_{1-6}alkylcarbonylamino, aminosulfonyl, mono- or di(C_{1-6}alkyl)-aminosulfonyl, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxy-carbonyl; R^7 and R^8 are each independently hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkyloxy or R^7 and R^8 taken together may form mono- or di(cyano)methylene, or together with the carbon atom to which they are attached form a carbonyl or a spiro substituent; or R^7 and R^8 taken together may form methylene; R^{13} is hydrogen, C_{1-6}alkyl, or trifluoromethyl; R^{14} is hydrogen, C_{1-6}alkyl, cyano, or trifluoromethyl; n is zero to 6. These compounds were tested as mCPP-antagonists in rats. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.